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Abstract
Malaria is one of the most prevalent infectious diseases worldwide with more than 250 million cases and one million deaths
each year. One of the well-characterized malarial-related molecules is hemozoin (HZ), which is a dark-brown crystal formed
by the parasite and released into the host during the burst of infected red blood cells. HZ has a stimulatory effect on the
host immune system such as its ability to induce pro-inflammatory mediators responsible for some of the malaria related
clinical symptoms such as fever. However, the host serum proteins interacting with malarial HZ as well as how this
interaction modifies its recognition by phagocytes remained elusive. In the actual study, using proteomic liquid
chromatographic mass spectrometry (LC-MS/MS) and immunochemical approaches, we compared the serum protein
profiles of malaria patients and healthy individuals. Particularly, we utilized the malarial HZ itself to capture serum proteins
capable to bind to HZ, enabling us to identify several proteins such as apolipoprotein E (ApoE), serum amyloid A (SAA),
gelsolin, complement factor H and fibrinogen that were found to differ among healthy and malaria individual. Of particular
interest is LPS binding protein (LBP), which is reported herein for the first time in the context of malaria. LBP is usually
produced during innate inflammatory response to gram-negative bacterial infections. The exact role of these biomarkers
and acute phase responses in malaria in general and HZ in particular remains to be investigated. The identification of these
inflammation-related biomarkers in malaria paves the way to potentially utilize them as diagnostic and therapeutic targets.
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Introduction
Malaria is one of the major public health problems worldwide
affecting more than 250 million people causing over one million
deaths each year. Caused by the Plasmodium parasite and
transmitted through the bite of an infected female Anopheles
mosquito, malaria still remains to be a major public health burden
particularly to the developing nations [1].
In uncomplicated malaria cases, some of the malaria symptoms
include fever, chills, sweats, headache, nausea, vomiting and
general malaise. Severe P. falciparum mediated malaria, however, is
characterized by cerebral malaria, severe anemia, renal failure,
metabolic acidosis, and hyperparasitemia, where more than 5% of
the red blood cells (RBC) are infected by the parasites [2]. Severe
malaria, which is a complex multi-system disorder, has clinical
similarities with sepsis. For example, metabolic acidosis, which is
the excessive acidity in the blood and tissue fluids, is also observed
in severe malaria patients [3].
During malaria infection, several inflammatory mediators are
involved. The presence of high levels of pro-inflammatory
mediators such as TNF-a, IL-1b and IFN-c is correlated with
severe malaria [4]. Furthermore, there is a marked increase in
plasma concentrations of adhesion receptors such as ICAM-1 and
E-selectin [5]. In addition to cytokines, others biomarkers have
been used to discriminate cerebral malaria from uncomplicated
malaria, such as serum angiopoietin-1 and -2 (ANG-1 and ANG-
2). The levels of ANG-1 significantly decrease while ANG-2
increases in cerebral malaria patients [6,7]. Moreover, ANG-2,
which is the angiogenic factor modulating endothelial activation, is
significantly elevated in severe malaria patients [8].
Elevated levels of serum and cerebrospinal fluid apoptotic
factors such as IP-10 (INF-inducible protein 10 KDa), IL-1ra,
sTNF-R1, sTNF-R2 and sFas were also correlated with cerebral
malaria-associated mortality in children [9]. Peripheral levels of
IL-10, TNF-a and ferritin were elevated in inflammatory placental
malaria whereas the level of leptin showed a marked decrease [10].
In this line of thought, discovery of biomarkers could help to
discriminate malaria severity, as well as their role in the
development of malaria-related pathologies in conjunction with
parasite bi-product such as hemozoin (HZ).
During its intraerythrocytic stage, the obligate intracellular
malaria parasite utilizes hemoglobin of the RBCs. This hemoglo-
bin proteolysis results in the production of toxic free heme and the
parasite developed a heme detoxification mechanism that results
in the formation of heme dimmers, called HZ [11]. Each
erythrocytic cycle in a malaria patient with 1–10% parasitemia
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infection, HZ is released into the circulation with the merozoites
during the rupture of infected RBCs and it induces the production
of several proinflammatory molecules in vitro and in vivo [13].
When considering the physicochemical characteristics of HZ
crystal, it has been shown to bind lipids, DNA and proteins. HZ
has also been produced synthetically, showing the same biological
and chemical characteristics as the native one [14]. When it is
released into the bloodstream, it comes in contact with several host
serum proteins, however, whereas preliminary analysis revealed
that native HZ prior to its released in circulation is solely covered
by globin fragments (Bellemare et al., unpublished data), the
identity of these proteins is still unrevealed.
In the present work, we used the synthetic HZ to capture and
identify HZ-binding serum proteins, which can also serve as to
discover unique biomarkers related to malaria context. Our
analysis have permitted to identify 42 proteins binding to HZ,
among which we confirm the presence of previously reported
biomarkers such as serum amyloid A (SAA) and gelsolin. In
addition, we identified new malaria biomarkers such as LPS
binding protein (LBP), apolipoprotein E (ApoE) and alpha-1-
antitrypin as well as proteins that are absent in the malaria sample
such as clusterin and complement B. Identification of new malaria
biomarkers during malaria infection permit us to identify a specific
protein profile signature that could be useful for the development
of rapid diagnostic tests, and further our understanding in regard
to the development of inflammatory-related malaria pathologies.
Materials and Methods
Serum samples
Individuals with positive blood smear for P. falciparum were eligible
for enrollment. The institutional ethics committee at the Parasitology
and Mycology Service of Faculty of Medicine, Cheikh Anta Diop
University, Dakar, Senegal granted ethics approval. Written and
verbal consent were obtained prior to the experiments. Written
informed consents were obtained from the patients or their legal
guardians and in the cases where written consents were not possible
verbal consents were obtained. Venous blood samples were collected
and serum derived from patient blood was immediately frozen,
shipped on dry ice, and maintained at 280uC until use at the National
Reference Center for Parasitology of the Research Institute of McGill
University Health Center, Montre ´al, Canada. The institutional review
board of McGill University approved the study. The sera used were
thawed on ice and re-frozen a maximum of two times.
Hemozoin preparation
HZ was prepared according to [15]. Briefly, hemin (0.8 mmol,
500 mg) was dissolved in degassed NaOH (0.1 M, 100 mL) for
30 min, with mild stirring. Propionic acid (4 ml) was added drop-wise
over a 20 min period until a pH of about 4 was achieved. The mixture
was allowed to anneal at 70uC for 18 hours. Then the following
washes were performed: Three NaHCO3 (0.1 M) washes for 3 hours
alternating each ones with dH2O. Finally, methanol and dH2Ow e r e
used for washing 3 times alternatively. The sample was then
thoroughly dried in a vacuum oven overnight over phosphorous
pentoxyde. All synthetic hemozoin samples were fully characterized by
X-ray powder diffraction (XRD), field emission gun scanning electron
microscopy (FEG-SEM), and infra-red spectroscopy (ATR-FTIR).
Coating hemozoin with serum
To identify serum proteins interacting with HZ, we used at least
8 individual serum samples from mild malaria patients, severe
malaria patients, or healthy individuals. Hundred micrograms of
HZ was coated with 10% serum in the presence of MEM medium
(Gibco), with a final volume of 100 ml. Serum proteins were
allowed to bind to HZ by incubating them at 37uC for 30 min.
Unbound proteins were removed by washing with 500 mlo f
phosphate buffered saline (PBS) at 45006g for 5 min. The washing
and centrifugation was repeated four times to ensure the maximal
removal of unbound proteins. After the last wash, each sample was
subject to SDS-PAGE followed by silver staining or Western
blotting analysis; and mass spectrometry analysis.
Silver staining
HZ-bound proteins were resolved by standard 12% SDS-
polyacrylamide gel and subsequently visualized by silver staining
as described by [16] with slight modification. After electrophoresis,
the gel slab was first fixed in 40% methanol/5% acetic acid for
20 min followed by washing with 30% methanol for 10 min. The
washing was repeated with water for 10 min to remove the
remaining acid. Gel sensitization was achieved by 1 min
incubation in 0.02% sodium thiosulphate, followed by 2 washes
with distilled water for 1 min each. The gel was then submerged in
0.2% silver nitrate solution and incubated for 30 min at RT. After
incubation, the silver nitrate was discarded; the gel slab was rinsed
twice with water for 1 min and developed in 37% formaldehyde;
3% sodium carbonate and 0.001% Sodium thiosulphate solution.
When the desired intensity of staining was achieved, development
was stopped by discarding the reagent and adding 3% TRIS base/
2% acetic acid solution for 30 min followed by 1% acetic acid
storage solution. All the solutions used were prepared in water and
the gel slab was shaking in orbital shaker in all the described steps.
Western blotting and LPS binding protein (LBP) ELISA
SDS-polyacrylamide gel resolved HZ-bound proteins were
transferred to PVDF membranes. After blocking, membranes
were immunoblotted with anti-SAA (Santa Cruz Biotechnology,
CA), Apo E (Millipore), albumin (Santa Cruz Biotechnology, CA),
and LBP (Santa Cruz, CA) antibodies and appropriate secondary
antibody conjugated with HRP (from Sigma). Total serum LBP
levels (without HZ binding) were determined using commercially
available human LBP ELISA kit (HyCult Biotechnology) accord-
ing to the manufacturer’s instruction.
Liquid chromatography-mass spectrometry (LC/MS/MS)
In-solution protein digestion. Protein-coated HZ crystals
were subjected to a manual in-solution digestion before analysis by
mass spectroscopy at the McGill University and Genome Quebec
Innovation Center. Briefly, each tube containing HZ crystal-
adsorbed protein solutions were air-dried (SpeedVac). Pellets were
resuspended in a 50 mM ammonium bicarbonate buffer (pH 7.8)
supplemented with 6 M urea for the proteins to be denatured. One
hundred mM DTT in 50 mM ammonium bicarbonate buffer was
then added to each tube to a final concentration of 10 mM DTT.
Samples were incubated for 30 min for 37uC then cooled for 5 min
at RT. After a quick spin, 300 mM iodoacetamide in 50 mM
ammoniumbicarbonatebufferwasaddedtoafinalconcentrationof
27.5 mM iodoacetamide and incubated for 30 min at RT in the
dark. The reduced and alkylated samples were diluted to a final
concentration of 1.5 M urea with 50 mM ammonium bicarbonate
buffer. Digestion was performed by the addition of trypsin at a ratio
of 1:25 (w/w) protease:protein. After an overnight incubation at
37uC, the reaction was quenched by the addition of formic acid to a
final concentration of 1%. Samples were then cleaned using Zip Tip
C18 before mass spectrometry analysis.
Mass spectrometry. Extracted peptides were subjected to
mass spectrometry analysis as subsequently described. Eluted
Malaria Biomarkers in Human
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column and peptides were subsequently resolved on a 10 cm675
micron PicoFrit column containing BioBasic C18 packing. Peptides
wereeluted from the column with a 30 minutes gradient of 10–95%
acetonitrile (v/v) containing 0.1% formic acid (v/v) at a flow rate of
200 nl/min using an Agilent 1100 series NanoHPLC system
(Mississauga, ON). Eluted peptides were electrosprayed as they
exited the column. Mass spectrometric data were acquired on a
QTRAP 4000 (SCIEX/ABI, Concord, ON) using the Information
Dependent Analysis (IDA) feature of Analyst 1.4.1 software (ABI,
Foster city, CA). Precursor ion selection for subsequent tandem ms
fragmentation analysis was done using predefined IDA criteria.
Briefly, up to three doubly, triply or quadriply charged ions of
intensity greater than 2610
6 counts per second (cps) from each
enhanced-ms survey scan were selected for passage into a collision
cell. Collision-induced dissociation was facilitated by collision with
nitrogen gas; fragment ions weretrapped in Q3 and scanned. Three
enhanced-product ion scans (EPI) at a speed of 400 amu/second
from 70to 1700 m/zwere averaged foreachselected precursor ion.
Accumulation time used for EPI scans was 20 ms with Q0 trapping
activated. MS/MS raw data were transferred from the QTrap 4000
linear ion trap mass spectrometer to a 50 terabytes server and
automatically manipulated for generation of peak lists by employing
Distiller version 2.1.0.0 (http://www.matrixscience.com/distiller.
html) software with peak picking parameters set at 1 as for Signal
Noise Ratio (SNR) and at 0.3 for Correlation Threshold (CT).
Protein database searching. The peak-listed data was then
searched against a copy of the Universal Protein Resource
(UniPort) database (March 03, 2008) by using Mascot (Matrix
Science, London, UK; version 2.1.4.04) and X! Tandem (http://
www.thegpm.org version 2007.01.01.1). Mascot was set up to
search the Homo sapiens (taxon ID 9606) database (71371 entries;
28450293 residues) assuming the digestion enzyme trypsin. X!
Tandem was set up to search a subset of the Homo sapiens (taxon ID
9606) also assuming trypsin. Mascot and X! Tandem were
searched with a fragment ion mass tolerance of 0.80 Da and a
parent ion tolerance of 1.5 Da. Iodoacetamide derivative of
cysteine was specified in Mascot and X! Tandem as a fixed
modification. Oxidation of methionine was specified in Mascot as
a variable modification. Pyro-glu from Q of glutamine,
deamidation of asparagine and oxidation of methionine were
specified in X! Tandem as variable modifications.
Protein identification. Scaffold (version 2, Proteome
Software Inc., Portland, OR) was used to validate MS/MS
based peptide and protein identifications. Peptide identifications
were accepted if they could be established at greater than 95%
probability as specified by the Peptide Prophet algorithm [17].
Protein identifications were accepted if they could be established at
greater than 90% probability and contained at least 1 identified
peptide. Protein probabilities were assigned by the Protein Prophet
algorithm [18]. Proteins that contained similar peptides and could
not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony.
Blast2GO analysis
Bioinformatics analysis was carried out using Blast2GO, a Gene
Ontology (GO) annotation, visualization and analysis software
(version 1.2.7 http://web3.vs160142.vserver.de). The analysis
consists of three sequential steps: basic local alignment search tool
(BLAST), mapping and annotation.
Blast. The sequences proteins identified by the mass
spectrometry were retrieved from Universal Protein Resource
(UniProt) database (www.uniprot.org) and were saved as fasta files,
since the blast server accepts only fasta-formatted protein sequences
as input queries. The protein input queries were blasted against the
NCBI Basic Local Alignment Search Tool (BLAST) database
http://www.ncbi.nlm.nih.gov/BLAST/to find similar sequences.
The input parameters used were as follows: BLAST database,
NCBI nr; number of BLAST hits requested for each query, 20;
BLAST expectValue (i.e. eValue), 1e-3; BLAST program, blastp;
Blast Mode: QBlast-NCBI; HSP length cutoff: 33.
Mapping. Mapping was performed using Blast2GO to obtain
Gene Ontologies (GO) for hits retrieved by the Blast step. The
mapping step searches various databases and over 2 million gene
products to identify and fetch GO terms.
Annotation. The annotation procedure selects the GO terms
from the GO pool obtained by the mapping step and assigns them
to the query sequences, using the Annotation Rule. The
annotation parameters were: Pre-eValue-Hit-Filter, 6; Pre-
Similarity-Hit-Filter, 30; Annotation Cut-Off, 55; GO-Weight, 5.
Statistical analysis
Data was analysed using GraphPad Prism 5.0. Unpaired t-test
was used for the comparison of two parameters. For the
comparison of more than two parameters, one-way ANOVA
was employed followed by Bonferroni’s multiple comparison test.
Means were considered significant for P-values ,0.05.
Results
Sample categorization and visualization of hemozoin-
binding proteins
Malaria complications can be divided into severe and mild
according to the parasitemia level. In the present work, patient
serum samples used were classified into two groups: mild and severe
malaria. The classification is based on the level of parasitemia,
taking 5% as a cutoff value, as shown in Figure 1. Sera from non-
infected individuals were used as control (healthy group).
Figure 1. The level of parasitemia (%) of the malaria patients.
Malaria patients were grouped into mild and severe based on the level
of parasitemia (%). Patients with levels below 5% were grouped into
mild and above as severe. Each data point represents individual patient.
Sera from eight mild malaria and eight from severe malaria patients
were used to identify hemozoin-binding proteins. **P=0.0002.
doi:10.1371/journal.pone.0026495.g001
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HZ, a synthetic HZ was incubated with serum samples from
healthy individuals and malaria patients, and the protein-coated
HZ crystal was run onto gel followed by silver staining. As shown
in Figure 2, the protein profile of healthy individuals differs
substantially from the malaria patients suggesting that proteins
adhering to HZ are in part clearly different.
Identification of malaria biomarkers associated with
hemozoin
In order to identify the proteins, the protein-coated HZ was
eluted,separatedbyliquidchromatography(LC)anddetected using
LC-coupled tandem mass spectrometry (LC-MS/MS). Database
searching (Mascot and X! Tandem) was performed for protein
identification, as outlined in the Materials and Methods section.
We used the Scaffold 2 Proteome software to visualize, validate,
and analyze the identified HZ-binding proteins. A total of 75
proteins were identified. A 95% peptide identification probability
and 90% protein identification probability were used as cutoffs for
Scaffold. This analysis yielded 42 proteins, excluding the others
identified with lesser probability. The complete list of the identified
HZ-binding proteins along with their accession number, molecular
weights and the mean 6 SEM of the normalized spectrum count
are shown in Table 1. The identified proteins include lipid binding/
transport proteins, acute phase proteins, immunoglobulins, and
complement component proteins. HZ-binding proteins were not
significantly different between the mild and severe malaria.
However, 24 from the 42 identified proteins were significantly
different from control and malaria groups. The comparison was
done basedonthenormalized spectrumcounts(i.e.spectrumcounts
divided by the total number of filter-passing peptide identifications
from each phase), calculated by Scaffold software and further
statistic analysis. Some specific examples of malaria biomarkers
bound to HZ included LPS binding protein (P18426), apolipopro-
tein E (P02649), hemoglobin subunit alpha (P69905), serum
amyloid A (P02735) and complement factor H (A5PL14).
The total number of unique peptides identified for each protein
in the mild, severe, and healthy groups was used to compare the
presence and abundance of each protein among the different
groups. The distribution of the 42 HZ-binding proteins among the
different groups (mild, severe and control) was also calculated. The
distribution of the HZ-binding proteins identified in each group
and the overlap between the different groups (control, mild and
severe malaria) is shown in Figure 3A using Venn diagram. From
this distribution analysis we did not observe a major difference
between mild or severe malaria, at the exception of hemoglobin
subunits alpha and beta. Most of the proteins (29 proteins) overlap
between control and malaria group, two between control and
mild, and three between control and severe malaria. Based on this
distribution subsequent analysis was based on control and malaria
groups.
Functional analysis of HZ-binding proteins
In addition to distribution and abundance, functional analysis of
the hemozoin-binding proteins was performed using Blast2GO
(B2G), which is a comprehensive bioinformatics tool for functional
annotation and analysis of protein sequences. The B2G analysis
allowed us to elucidate the different functions and process in which
the HZ-binding proteins are putatively involved. The 42 identified
proteins were classified by their cellular (Figure 3B) and molecular
function (Figure 3C) as well as by their cellular component
(Figure 3D). Concerning cellular function, the identified proteins
were involved in cellular process (16%), response to stimulus
(16%), metabolic process (13%), biological regulation (13%) and
localization (11%). Interestingly, according to the molecular
function analysis (Fig. 3C), most of the proteins bound to HZ
were related with binding (46%), transport (19%) or enzyme
regulator activity (17%). In addition, most of the HZ-binding
proteins were found in the extracellular (54%) or cell region (25%)
as shown in Figure 3D by cellular component analysis.
Apart from the distribution of the identified HZ-binding
proteins, further analysis was performed to compare their relative
abundance across the different samples. For this we used the
normalized spectrum counts of each identified protein and showed
in histogram graphs for selected proteins bound to HZ. As shown
in Figure 4, the peptides of LBP (Figure 4A), apolipoprotein E
(Figure 4B), serum amyloid A (Figure 4C), alpha-1-antitrypsin
(Figure 4D) and hemoglobin subunit alpha (Figure 4F) were found
to be significantly higher in samples from malaria patients. On the
other hand, clusterin (Figure 4E) and complement C4B (Figure 4G)
were found only in the serum from control group. As expected,
serum albumin is evenly distributed (Figure 4H). This analysis
confirms the distribution of the proteins that could overlap
between control and malaria group, however the abundance the
proteins can be different according to the sample and group.
Validating the association of malaria biomarkers with
hemozoin
To confirm the mass spectrometric findings, selected HZ-
binding biomarkers and whole serum were subjected to Western
Figure 2. Silver-stained gel showing the profile of hemozoin-
binding proteins. Hemozoin was coated with serum from malaria
patients (mild and severe) and healthy individuals. The protein-coated
hemozoin crystal was subjected to 12% SDS-PAGE and silver-stained.
The protein profiles were different among the groups. The hemozoin
crystal alone (HZ), used as a control, is shown in the first lane. C1–C3:
sera from healthy individuals; M1–M3 sera from mild malaria; S1–S3 sera
from severe malaria patients.
doi:10.1371/journal.pone.0026495.g002
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Protein name
Protein
accession
number
Swiss-Prot
accession
number
MW
(kDa) Normalized spectrum count P-value
Control
(n=7)
Mild
malaria (n=8)
Severe
malaria (n=8)
Mean ± SEM Mean ± SEM Mean ± SEM
1 Alpha-1-antitrypsin A1AT_HUMAN P01009 47 2.3360.90 8.6662.40 12.2162.21 0.0049*
2 Alpha-2-macroglobulin A2MG_HUMAN P01023 163 0.5760.20 0.7060.53 1.8260.74 0.3512
3 Apolipoprotein A-I APOA1_HUMAN P02647 31 21.3065.62 13.4962.03 14.6561.27 0.0864
4 Apolipoprotein A-II APOA2_HUMAN P02652 11 3.9661.40 1.6060.91 4.6761.27 0.6077
5 Apolipoprotein A-IV APOA4_HUMAN P06727 45 1.7060.35 0.6560.37 0.6460.34 0.0251*
6 Apolipoprotein B C0JYY2_HUMAN C0JYY2 516 4.9762.32 9.2062.52 6.6362.10 0.3210
7 Apolipoprotein C-II APOC2_HUMAN P02655 11 0.9260.39 0 0.2560.16 0.0096*
8 Apolipoprotein C-III APOC3_HUMAN P02656 11 0.9260.16 0.7960.24 0.3060.20 0.1850
9 Apolipoprotein E APOE_HUMAN P02649 36 3.6860.72 8.5161.13 5.4161.06 0.0270*
10 Apolipoprotein L1 APOL1_HUMAN O14791 44 0 0.4760.23 0.3260.22 0.1109
11 Clusterin CLUS_HUMAN P10909 52 3.1560.30 0 0 ,0.0001*
12 Complement C1q subunit C C1QC_HUMAN P02747 26 1.1960.57 0.3460.22 0 0.0217*
13 Complement C3 CO3_HUMAN P01024 187 5.5061.21 1.8560.38 2.2660.59 0.0014*
14 Complement C4-B CO4B_HUMAN P0C0L5 193 3.6361.11 0 0.2060.20 ,0.0001*
15 Complement component C8 CO8B_HUMAN P07358 67 0.1860.18 0.5060.35 0.2860.18 0.5153
16 Complement component C9 CO9_HUMAN P02748 63 0.5060.35 0 0 0.0351*
17 Fibrinogen alpha chain FIBA_HUMAN P02671 95 7.1162.71 14.2162.53 15.4562.25 0.0198*
18 Fibrinogen beta chain FIBB_HUMAN P02675 56 1.2860.53 5.4061.46 4.5661.18 0.0177*
19 Fibrinogen gamma chain FIBG_HUMAN P02679 52 4.5761.89 9.5560.99 7.9360.93 0.0170*
20 Fibronectin FINC_HUMAN P02751 263 0.6860.50 0 0 0.0472*
21 Gelsolin GELS_HUMAN P06396 86 3.9061.97 0.8360.45 0.5860.32 0.0256*
22 Hemoglobin subunit alpha HBA_HUMAN P69905 15 0.1460.14 0.3560.35 2.0460.96 0.2192
23 Hemoglobin subunit beta HBB_HUMAN P68871 16 0.2560.25 0.7260.55 2.7260.90 0.1116
24 Histidine-rich glycoprotein HRG_HUMAN P04196 60 4.1560.75 1.6460.49 3.8761.07 0.2154
25 Ig gamma-1 chain C region IGHG1_HUMAN P01857 36 2.0560.61 0.6660.25 1.2760.33 0.0454*
26 Ig gamma-3 chain C region IGHG3_HUMAN P01860 41 0.8260.33 0.1360.13 0 0.0039*
27 Ig kappa chain C region IGKC_HUMAN P01834 12 1.8060.74 1.0560.35 1.7260.51 0.5469
28 Ig lambda chain C regions LAC_HUMAN P01842 11 0.9860.32 0.3060.20 0.2560.16 0.0212*
29 Ig mu chain C region IGHM_HUMAN P01871 49 0.7060.26 0.9360.33 1.1460.24 0.3452
30 Inter-alpha-trypsin inhibitor H2 ITIH2_HUMAN P19823 106 0.1460.14 0.6960.37 1.8860.79 0.1126
31 Inter-alpha-trypsin inhibitor H4 ITIH4_HUMAN Q14624 103 7.5561.51 0.9060.45 2.3661.45 0.0008*
32 Lipopolysaccharide-binding protein LBP_HUMAN P18428 53 0.5360.27 2.4660.54 2.6460.36 0.0008*
33 Platelet basic protein CXCL7_HUMAN P02775 14 0.6560.34 0 0 0.0074*
34 Platelet factor 4 PLF4_HUMAN P02776 11 1.2060.64 0 0.2560.16 0.0217*
35 Prothrombin THRB_HUMAN P00734 70 1.0460.56 0 0 0.0093*
36 Serum albumin ALBU_HUMAN P02768 69 7.4560.96 5.4061.05 8.4461.22 0.7226
37 Serum amyloid A protein SAA_HUMAN P02735 14 0.9860.47 3.8360.30 5.5961.21 0.0016*
38 Serum amyloid A-4 protein SAA4_HUMAN P35542 15 0.2960.18 0.2560.16 0.2060.20 0.7820
39 Sex hormone-binding globulin SHBG_HUMAN P04278 44 0 0 0.4560.23 0.2520
40 Thrombospondin-1 TSP1_HUMAN P07996 129 0.5260.37 0 0 0.0377*
41 Transthyretin TTHY_HUMAN P02766 16 1.4461.02 0.7460.36 1.8160.57 0.8472
42 Vitronectin VTNC_HUMAN P04004 54 7.3560.89 5.5961.26 6.0760.91 0.2500
The normalized spectrum counts shown is mean of seven control, eight mild malaria and eight severe malaria samples for each protein identified, as calculated by
Scaffold. P values indicate comparison of control versus malaria (mild and severe).
*Indicates significant difference between control and malaria patients (P,0.05). MW: molecular weight.
doi:10.1371/journal.pone.0026495.t001
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antibodies for serum amyloid A (SAA), apolipoprotein E (ApoE)
and serum albumin. As can be seen from Figure 5, the contact of
HZ with sera from malaria patient allows a higher binding with
SAA (Figure 5A) and ApoE (Figure 5B) compared to the controls.
The enhanced binding of these proteins to HZ might be related to
their concentration in the serum as whole serum showed the same
profile of SAA and ApoE. As control of protein binding and
loading, we used serum albumin. As shown in Figure 5C, albumin
was equally detected in the binding or whole sample from control
or malaria patients.
In addition to SAA and ApoE, we also performed the
Western Blotting analysis to LBP. As shown in Figure 6A, HZ
coated with sera from mild and severe malaria patients showed
a higher level of LBP compared to control sera. The total level
of LBP -directly in the whole sera without HZ binding- was also
quantified using sandwich ELISA specific for human LBP. As
s h o w ni nF i g u r e6 B ,t h el e v e lo fLBP measured was significantly
increased in malaria patients. Interestingly, and in contrast to
LBP, ApoE and SAA which are elevated in serum of malaria
patient, gelsolin was only found in serum from healthy
individuals and disappeared in the malaria samples (Figure
S1), suggesting that disappearance of normal serum proteins
during malaria could be advantageous to include in biomarker
profile related to malaria infection, since this reflects the
pathological condition.
This last set of experiments confirmed the findings from the
mass spectrometric analysis. Furthermore, Western Blotting results
further confirm that different proteins can bind to HZ and that
their binding levels correlate with the amount of protein present in
the serum, as revealed by the analysis of total protein. In addition,
the immunochemical analysis further revealed that the identified
biomarkers cannot differ substantially from severe and mildly
infected patients -at the exception for hemoglobin subunits alpha/
beta that were clearly elevated in serum of severe malaria patients-
but that it can clearly permit the discrimination between malaria
and healthy individuals as depicted by the peptide distribution
(Figure 4) and statistic analysis (Table 1).
Figure 3. The distribution of hemozoin-binding proteins among the different groups and Gene Ontology terms (level 2). The number
of hemozoin-binding proteins identified in each group (healthy controls, mild malaria, and severe malaria) and the distribution of the proteins among
the different groups is shown by Venn diagram (A). Sequences of hemozoin-binding proteins were blasted, mapped and annotated using Blast2GO
(B2G). A total of 701 Gene Ontology (GO) terms for biological process were identified, of which the distribution of the major ones is shown as
biological process (B), molecular function (C) and cellular component (D).
doi:10.1371/journal.pone.0026495.g003
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In the present work, we identified new inflammation related
biomarkers from the sera of malaria patients. Hemozoin, due to its
amphiphilic characteristic, has been described to bind to CpG DNA
[19] and proteins from the fetal bovine serum [13,14]. We devised a
novel way of screening potential biomarkers from the serum of
malariapatientsandhealthyindividualsusingthemalariaHZcrystal
totrapthesebiomarkers.Inthisway,wehavenotonlyidentifiednew
malaria-related biomarkers but also potential co-factors that
concomitantly with HZ could play a role in the modulation of
inflammatory and innate immune responses during malaria.
Previous works explored biomarkers for malaria infection,
particularly serum amyloid A (SAA) and C reactive protein (CRP)
were identified as important malaria biomarkers [20]. In fact, SAA
along with CRP has been proven to be valuable in assessing the
severity of malaria and particularly as a prognostic tool in
Figure 4. Normalized spectrum counts for selected hemozoin-binding proteins. Normalized spectrum counts, depicting the protein’s
relative abundance, is shown for selected hemozoin-binding proteins. A) LPS binding protein (LBP); B) Apoliporotein E (ApoE); C) serum amyloid A
(SAA); D) alpha-1-antitrypsin; E) Clusterin; F) hemoglobin subunit alpha; G) Complement factor C4B and H) serum albumin shown as a control. LBP,
ApoE, SAA, hemoglobin subunit alpha and alpha-1-antitrypsin were found in higher level in malaria patients whereas clusterin and complement C4B
were present only in control samples. *P,0.05 for control vs. malaria (mild and severe).
doi:10.1371/journal.pone.0026495.g004
Malaria Biomarkers in Human
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26495Figure 5. Western blots for selected biomarkers. Sera from mild and severe malaria patients and healthy individuals were either coated with
hemozoin or run onto gel directly for western blot analysis. The membranes were blotted using specific antibodies for A) Serum amyloid A (SAA), B)
Apolipoprotein E (ApoE) and C) serum albumin C1–C5: control; M1–M6: mild malaria; S1–S6: severe malaria.
doi:10.1371/journal.pone.0026495.g005
Figure 6. Confirmation of LPS binding protein using ELISA. A) Sera from mild and severe malaria patients and healthy individuals were
coated with hemozoin and run onto gel for western blot analysis. B) The level of LPS binding protein (LBP) from sera of six mild, six severe malaria
patients and six healthy individuals was quantified using sandwich ELISA. **P,0.05 for control vs. mild and control vs. severe.
doi:10.1371/journal.pone.0026495.g006
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detected SAA binding with hemozoin, but not CRP. The absence
of lipid-binding domain in CRP could explain its failure to interact
with hemozoin. SAA is an acute phase protein whose level
increases during infection. Indeed, our results show that, SAA
levels increase in the serum of malaria patients. SAA is a
multifunctional protein which is involved in cholesterol transport
and metabolism as well as inflammatory response [21].
The level of Apolipoprotein E (Apo E) also markedly increased
in malaria patients. ApoE binds to lipids to form molecules called
lipoproteins and known to be in part responsible for packaging
cholesterol and other fats carrying them through the bloodstream.
ApoE is a major component of a specific type of lipoprotein called
very low-density lipoproteins (VLDLs) which remove excess
cholesterol from the blood and carry it to the liver for processing.
ApoE also serves as a ligand for low density lipoprotein receptors
(LDLR) and ApoE receptor expressed in the hepatocytes (liver
cells) [22]. Whether ApoE plays a critical role to tame malaria-
related inflammatory responses or to detoxify the system from HZ,
is still to be investigated.
More importantly, we report herein for the first time the up-
regulation of LPS binding protein (LBP) in malaria. This latter is
usually produced and secreted by the liver in response to Gram
negative bacteria infection and particularly to the bacterial
endotoxin LPS. LBP binds and transfers LPS to Toll-like
receptor-4 (TLR-4) triggering an important signaling cascades
and activation of inflammatory and innate immune response.
Importantly, the level of LBP has been used as an important
biomarker in sepsis and septic shock patients, where its levels
increase up to 10-fold. Interestingly, depending on its level,LBP can
be detrimental to the host at low-levels whereas beneficial in high
amounts by detoxifying the system from LPS. Our findings, in the
context of malaria, also suggest that LBP in conjunction with other
identified proteins can be used as an important malaria biomarker.
Furthermore, this finding supports the idea that malaria inflamma-
tory disorder is often comparable to septic shock syndrome.
Other biomarkers identified include alpha-1-antitrypsin, clus-
terin, hemoglobin subunit alpha/beta and the complement C4B.
The level of alpha-1-antitrypsin, which is an inhibitor of serine
proteases, increases in malaria patients. On the other side, clusterin
-also known as Apolipoprotein J- is completely absent from the sera
of malaria patients. The function of clusterin in the context of
malaria diseases is not yet clear. However, it is known to be
expressed in a variety of tissues and is able to bind to cells,
membranes and hydrophobic proteins. Its interaction with
hydrophobic proteins might explain its binding ability to hemozoin,
whereas its disappearance from malaria patients can confer an
important role in the profiling of biomarkers related to malaria.
As malaria is characterized by a large number of red blood cell
destruction, the levels of hemoglobin subunit alpha and beta were
significantly elevated in malaria patients. Furthermore, this
difference is pronounced when comparing mild and severe malaria
patients, which correlates perfectly well with the level of infected red
blood cells and anemia. The destruction of erythrocytes results also
in the release of actin into the plasma. The actin-scavenging protein
called gelsolin clears the excess actin. However, if the rate of
clearance of actin-gelsolin complexes exceeds its synthesis, lowering
of gelsolin levels will follow. Apart from actin binding function, our
findings showed that gelsolin also binds hemozoin. This suggests
that hemozoin-gelsolin complexes may also contribute to the
depressed gelsolin levels observed during malaria.
Finally, complement activation in malaria is a well-documented
phenomenon. Previous studies have shown that complement
components C1q, C4, C3 and C5a change in malaria patients. In
line with previous findings [24], our results also confirm
complement C1q consumption in malaria patients. Furthermore,
depletion of complement C3 was reported in severe and
uncomplicated malaria patients as compared to healthy controls
[23–27]. Collectively, those last observations further reinforce the
validity of our study with the goal to identify new malaria related
biomarkers.
As far as the scientific literature is concerned, there has not been
any report that identifies serum proteins interacting with HZ.
Hence apart from the biomarker discovery, our approach also aids
in revealing the identity of serum proteins interacting with HZ.
Even though much is known about the effect of HZ in the host
immune system (as outlined in detail in the Introduction section),
the role of HZ-binding proteins in the recognition, immune
modulation and physiological clearance of HZ is unrevealed.
Hence, the identification of HZ-binding proteins will help in
elucidating the complete role of this inorganic crystal in the human
host during malaria pathology.
In conclusion, we have identified specific HZ-binding proteins
from serum of malaria patients and healthy individuals that can be
useful to develop new assay based on profile of malaria
biomarkers. The role of HZ-binding proteins in the crystals’
recognition by the immune system and its clearance remains to be
investigated in a near future. Collectively, we believed that our
actual study bring in a new devise that can be very helpful to
concomitantly identify biomarkers related to malaria and to
develop a specific biomarker-based diagnostic tool.
Supporting Information
Figure S1 Western blots for selected biomarkers. Sera
from malaria patients and healthy individuals were coated with
hemozoin and run onto gel for western blot analysis. The
membranes were blotted using specific antibodies for gelsolin,
LPS binding protein (LBP), Serum amyloid A (SAA), Apolipopro-
tein E (ApoE) and serum albumin. C1–C8: control; M1–M8:
malaria.
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